NCT04918121 is a EARLY_PHASE1 clinical trial of Yutiq 0.18 MG Drug Implant in Glaucoma, sponsored by Sanjay Asrani.

Who is sponsoring NCT04918121?

NCT04918121 is sponsored by Sanjay Asrani.

What drugs are being tested in NCT04918121?

Interventions in NCT04918121: Yutiq 0.18 MG Drug Implant.

Is NCT04918121 still recruiting?

NCT04918121 is currently active, enrolled. Last updated 6 November 2025.

Last reviewed 2025-11-06 · How we verify

NCT04918121

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery

Active, enrolled EARLY_PHASE1 Last updated 6 November 2025

What this trial tests

EARLY_PHASE1 trial testing Yutiq 0.18 MG Drug Implant in Glaucoma in 5 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 July 2021

Primary endpoint
1 June 2027

1 June 2027

Quick facts

Lead sponsor	Sanjay Asrani
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	20 July 2021
Primary completion	1 June 2027
Estimated completion	1 June 2027
Sites	1 location across United States

Drugs / interventions tested

Yutiq 0.18 MG Drug Implant — full drug profile →

Conditions studied

Glaucoma — all drugs for Glaucoma →

Sponsor

Sanjay Asrani

Who can join

18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in IOP measured using Goldman applanation tonometry
Time frame: week 12, month 6, month 12, month 18, month 24, month 30 , month 36
IOP in study eyes compared to eyes undergoing the same surgery without the Yutiq insert
Change in IOP measured using tonopen/Icare
Time frame: week 12, month 6, month 12, month 18, month 24, month 30 , month 36
IOP in study eyes compared to eyes undergoing the same surgery without the Yutiq insert
Medications usage as measured by medical record abstraction
Time frame: week 12
Number of medications to control IOP in the study eye
Medications usage by medical record abstraction
Time frame: month 6
Number of medications to control IOP in the study eye
Medications usage by medical record abstraction
Time frame: month 12
Number of medications to control IOP in the study eye
Medications usage by medical record abstraction
Time frame: month 18
Number of medications to control IOP in the study eye

Sponsor's own description

This is a pilot study, which will include approximately five eyes of 5 patients. This study proposes that a sustained release steroid insert (Yutiq)1 be implanted along with a glaucoma drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery. The primary aim of this study is to assess the safety and efficacy (controlling intraocular pressure) of the Yutiq inserts to reduce post-operative scarring in surgical glaucoma patients. It is expected that post-operative week 12 onwards there will be a clinically and statistically significant lower IOP in the study eyes than eyes in a group undergoing the same surgery without the Yutiq insert. The estimated duration of the present study is 3 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04918121 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanjay Asrani
Last refreshed: 6 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04918121.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing